In-vitro Colorectal Cancer Screening Tests Market Report by Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), Imaging Type (Colonoscopy, Proctoscopy, CT Scan, Ultrasound, MRI, PET Scan), End User (Hospitals, Clinics, Diagnostic

In-vitro Colorectal Cancer Screening Tests Market Report by Product (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), Imaging Type (Colonoscopy, Proctoscopy, CT Scan, Ultrasound, MRI, PET Scan), End User (Hospitals, Clinics, Diagnostic Laboratories, and Others), and Region 2024-2032

The global in-vitro colorectal cancer screening tests market size reached US$ 997.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,590.8 Million by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.

In-vitro colorectal cancer screening tests are diagnostic procedures performed to detect adenomas, polyps and symptoms of colorectal cancer. Colorectal cancer refers to a medical condition that is characterized by the abnormal growth of cells in the large intestine, colon and rectum. Fecal occult blood (FOB), lateral flow immuno, transferrin assays, methylated gene, biomarker and guaiac FOB stool test are some of the commonly performed screening tests. In-vitro colorectal cancer screening tests involve the use of cameras that capture images of the digestive tract and transfers them to the recorder tied to the waist of the patient. They are minimally invasive and can aid in timely detection of cancer. As a result, in-vitro colorectal cancer screening tests are widely performed across clinics, hospitals and diagnostics laboratories.

In-Vitro Colorectal Cancer Screening Tests Market Trends:
The increasing prevalence of colorectal cancer among the masses is one of the key factors driving the growth of the market. Moreover, rising awareness regarding the benefits of early detection and timely treatment of cancer is positively impacting the market growth. Various technological advancements, such as the integration of genetic testing in cancer screening tests, are providing a thrust to the market growth. These tests aid in early detection, developing treatment plans, preventing the spread of cancerous cells and minimizing the risks of developing associated disorders. In line with this, the increasing preference for minimally invasive (MI) diagnostic procedures to detect colorectal cancer is favoring the market growth. Other factors, including rising geriatric populations, which is more susceptible to such ailments and significant improvements in the healthcare industry, along with the implementation of various government initiatives mandating cancer screening tests, are anticipated to drive the market toward growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global In-vitro colorectal cancer screening tests market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, imaging type and end user.

Breakup by Product:

Fecal Occult Blood Tests
Guaiac FOB Stool Test
Immuno-FOB Agglutination Test
Lateral Flow Immuno-FOB Test
Immuno-FOB ELISA Test
Biomarker Tests
Tumor M2-PK Stool Test
Transferrin Assays
CRC DNA Screening Tests
Methylated Gene Testing
Panel DNA Tests

Breakup by Imaging Type:

Colonoscopy
Proctoscopy
CT Scan
Ultrasound
MRI
PET Scan

Breakup by End User:

Hospitals
Clinics
Diagnostic Laboratories
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Beckman Coulter Inc. (Danaher Corporation), Eiken Chemical Co. Ltd., Epigenomics AG, Exact Sciences Corporation, Hemosure Inc., Immunostics Inc. (Boditech Med Inc.), Medline Industries LP, Merck KGaA, Qiagen N.V., Quest Diagnostics Incorporated, R-Biopharm AG, Siemens AG and Sysmex Corporation.

Key Questions Answered in This Report

1. What was the size of the global in-vitro colorectal cancer screening tests market in 2023?
2. What is the expected growth rate of the global in-vitro colorectal cancer screening tests market during 2024-2032?
3. What has been the impact of COVID-19 on the global in-vitro colorectal cancer screening tests market?
4. What are the key factors driving the global in-vitro colorectal cancer screening tests market?
5. What is the breakup of the global in-vitro colorectal cancer screening tests market based on the product?
6. What is the breakup of the global in-vitro colorectal cancer screening tests market based on the imaging type?
7. What is the breakup of the global in-vitro colorectal cancer screening tests market based on end user?
8. What are the key regions in the global in-vitro colorectal cancer screening tests market?
9. Who are the key players/companies in the global in-vitro colorectal cancer screening tests market?